Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0WN3O
|
|||
Former ID |
DNC007273
|
|||
Drug Name |
N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutyramide
|
|||
Synonyms |
CHEMBL374366; 820961-71-5; N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutyramide; SCHEMBL6497567; CTK3E2637; DTXSID20461437; BDBM50157660; AKOS030569446; Butanamide, N-(4,6-diphenyl-2-pyrimidinyl)-2-ethyl-
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C22H23N3O
|
|||
Canonical SMILES |
CCC(CC)C(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
|
|||
InChI |
1S/C22H23N3O/c1-3-16(4-2)21(26)25-22-23-19(17-11-7-5-8-12-17)15-20(24-22)18-13-9-6-10-14-18/h5-16H,3-4H2,1-2H3,(H,23,24,25,26)
|
|||
InChIKey |
YOARGGKKYZIYSU-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 820961-71-5
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adenosine A1 receptor (ADORA1) | Target Info | Inhibitor | [1] |
KEGG Pathway | cGMP-PKG signaling pathway | |||
cAMP signaling pathway | ||||
Sphingolipid signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Morphine addiction | ||||
NetPath Pathway | TCR Signaling Pathway | |||
RANKL Signaling Pathway | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Reactome | Adenosine P1 receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | Nucleotide GPCRs | |||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.